INTEGRA LIFESCIENCES HOLDING (IART) Stock Fundamental Analysis
NASDAQ:IART - Nasdaq - US4579852082 - Common Stock - Currency: USD
Taking everything into account, IART scores 3 out of 10 in our fundamental rating. IART was compared to 187 industry peers in the Health Care Equipment & Supplies industry. There are concerns on the financial health of IART while its profitability can be described as average. IART has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
In the past year IART was profitable.
IART had a positive operating cash flow in the past year.
IART had positive earnings in 4 of the past 5 years.
Each year in the past 5 years IART had a positive operating cash flow.
1.2 Ratios
IART's Return On Assets of -0.71% is fine compared to the rest of the industry. IART outperforms 71.66% of its industry peers.
Looking at the Return On Equity, with a value of -1.90%, IART is in the better half of the industry, outperforming 72.19% of the companies in the same industry.
With a decent Return On Invested Capital value of 4.48%, IART is doing good in the industry, outperforming 76.47% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for IART is in line with the industry average of 7.89%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.71% | ||
| ROE | -1.9% | ||
| ROIC | 4.48% |
ROA(3y)2.09%
ROA(5y)2.89%
ROE(3y)4.61%
ROE(5y)6.54%
ROIC(3y)6.1%
ROIC(5y)6.15%
1.3 Margins
Looking at the Operating Margin, with a value of 10.34%, IART is in the better half of the industry, outperforming 77.54% of the companies in the same industry.
IART's Operating Margin has declined in the last couple of years.
The Gross Margin of IART (58.47%) is comparable to the rest of the industry.
IART's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 10.34% | ||
| PM (TTM) | N/A | ||
| GM | 58.47% |
OM growth 3Y-14.31%
OM growth 5Y-7.91%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.19%
GM growth 5Y-1.66%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so IART is destroying value.
IART has less shares outstanding than it did 1 year ago.
The number of shares outstanding for IART has been reduced compared to 5 years ago.
Compared to 1 year ago, IART has a worse debt to assets ratio.
2.2 Solvency
IART has an Altman-Z score of 1.12. This is a bad value and indicates that IART is not financially healthy and even has some risk of bankruptcy.
IART has a Altman-Z score (1.12) which is comparable to the rest of the industry.
A Debt/Equity ratio of 0.81 indicates that IART is somewhat dependend on debt financing.
IART has a worse Debt to Equity ratio (0.81) than 74.87% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.81 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.12 |
ROIC/WACC0.6
WACC7.41%
2.3 Liquidity
IART has a Current Ratio of 1.21. This is a normal value and indicates that IART is financially healthy and should not expect problems in meeting its short term obligations.
IART's Current ratio of 1.21 is on the low side compared to the rest of the industry. IART is outperformed by 82.35% of its industry peers.
IART has a Quick Ratio of 1.21. This is a bad value and indicates that IART is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of IART (0.72) is worse than 89.84% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.21 | ||
| Quick Ratio | 0.72 |
3. Growth
3.1 Past
IART shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -16.84%.
Measured over the past years, IART shows a decrease in Earnings Per Share. The EPS has been decreasing by -1.35% on average per year.
The Revenue has been growing slightly by 6.19% in the past year.
Measured over the past years, IART shows a small growth in Revenue. The Revenue has been growing by 1.20% on average per year.
EPS 1Y (TTM)-16.84%
EPS 3Y-6.97%
EPS 5Y-1.35%
EPS Q2Q%-25.45%
Revenue 1Y (TTM)6.19%
Revenue growth 3Y1.45%
Revenue growth 5Y1.2%
Sales Q2Q%3.74%
3.2 Future
IART is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 3.38% yearly.
IART is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 3.92% yearly.
EPS Next Y-10.77%
EPS Next 2Y-1.06%
EPS Next 3Y3.38%
EPS Next 5YN/A
Revenue Next Year3.34%
Revenue Next 2Y3.88%
Revenue Next 3Y3.92%
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 4.79, the valuation of IART can be described as very cheap.
97.86% of the companies in the same industry are more expensive than IART, based on the Price/Earnings ratio.
The average S&P500 Price/Earnings ratio is at 26.34. IART is valued rather cheaply when compared to this.
A Price/Forward Earnings ratio of 4.63 indicates a rather cheap valuation of IART.
Based on the Price/Forward Earnings ratio, IART is valued cheaply inside the industry as 98.93% of the companies are valued more expensively.
IART is valuated cheaply when we compare the Price/Forward Earnings ratio to 21.03, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 4.79 | ||
| Fwd PE | 4.63 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, IART is valued cheaper than 95.19% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 7.73 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-1.06%
EPS Next 3Y3.38%
5. Dividend
5.1 Amount
No dividends for IART!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
11.6
-0.31 (-2.6%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners96.59%
Inst Owner Change9.1%
Ins Owners3.32%
Ins Owner Change2.07%
Market Cap901.44M
Analysts54.44
Price Target17.05 (46.98%)
Short Float %8.08%
Short Ratio4.28
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)2.18%
Min EPS beat(2)-6.76%
Max EPS beat(2)11.12%
EPS beat(4)2
Avg EPS beat(4)1.7%
Min EPS beat(4)-6.76%
Max EPS beat(4)11.12%
EPS beat(8)3
Avg EPS beat(8)2.41%
EPS beat(12)5
Avg EPS beat(12)3.04%
EPS beat(16)8
Avg EPS beat(16)4.75%
Revenue beat(2)0
Avg Revenue beat(2)-2.05%
Min Revenue beat(2)-2.51%
Max Revenue beat(2)-1.58%
Revenue beat(4)0
Avg Revenue beat(4)-1.38%
Min Revenue beat(4)-2.51%
Max Revenue beat(4)-0.64%
Revenue beat(8)0
Avg Revenue beat(8)-1.35%
Revenue beat(12)1
Avg Revenue beat(12)-1.19%
Revenue beat(16)3
Avg Revenue beat(16)-0.84%
PT rev (1m)-17.02%
PT rev (3m)-36.33%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-25.52%
EPS NY rev (1m)0.05%
EPS NY rev (3m)-10.91%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-5.27%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.87%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 4.79 | ||
| Fwd PE | 4.63 | ||
| P/S | 0.55 | ||
| P/FCF | N/A | ||
| P/OCF | 8.81 | ||
| P/B | 0.59 | ||
| P/tB | N/A | ||
| EV/EBITDA | 7.73 |
EPS(TTM)2.42
EY20.86%
EPS(NY)2.51
Fwd EY21.6%
FCF(TTM)-0.33
FCFYN/A
OCF(TTM)1.32
OCFY11.36%
SpS20.9
BVpS19.61
TBVpS-9.89
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.71% | ||
| ROE | -1.9% | ||
| ROCE | 5.36% | ||
| ROIC | 4.48% | ||
| ROICexc | 4.91% | ||
| ROICexgc | 24.71% | ||
| OM | 10.34% | ||
| PM (TTM) | N/A | ||
| GM | 58.47% | ||
| FCFM | N/A |
ROA(3y)2.09%
ROA(5y)2.89%
ROE(3y)4.61%
ROE(5y)6.54%
ROIC(3y)6.1%
ROIC(5y)6.15%
ROICexc(3y)6.8%
ROICexc(5y)7%
ROICexgc(3y)25.35%
ROICexgc(5y)25.69%
ROCE(3y)7.3%
ROCE(5y)7.36%
ROICexcg growth 3Y-1.99%
ROICexcg growth 5Y0.59%
ROICexc growth 3Y-12.19%
ROICexc growth 5Y-7.26%
OM growth 3Y-14.31%
OM growth 5Y-7.91%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.19%
GM growth 5Y-1.66%
F-Score5
Asset Turnover0.4
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.81 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 3.9 | ||
| Cap/Depr | 86.65% | ||
| Cap/Sales | 7.87% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 32.45% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.21 | ||
| Quick Ratio | 0.72 | ||
| Altman-Z | 1.12 |
F-Score5
WACC7.41%
ROIC/WACC0.6
Cap/Depr(3y)58.38%
Cap/Depr(5y)54.07%
Cap/Sales(3y)4.82%
Cap/Sales(5y)4.45%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-16.84%
EPS 3Y-6.97%
EPS 5Y-1.35%
EPS Q2Q%-25.45%
EPS Next Y-10.77%
EPS Next 2Y-1.06%
EPS Next 3Y3.38%
EPS Next 5YN/A
Revenue 1Y (TTM)6.19%
Revenue growth 3Y1.45%
Revenue growth 5Y1.2%
Sales Q2Q%3.74%
Revenue Next Year3.34%
Revenue Next 2Y3.88%
Revenue Next 3Y3.92%
Revenue Next 5YN/A
EBIT growth 1Y-33.28%
EBIT growth 3Y-13.07%
EBIT growth 5Y-6.81%
EBIT Next Year16.37%
EBIT Next 3Y9.92%
EBIT Next 5YN/A
FCF growth 1Y-112.75%
FCF growth 3Y-61.56%
FCF growth 5Y-31.13%
OCF growth 1Y-58.45%
OCF growth 3Y-25.46%
OCF growth 5Y-10.98%